These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38222349)

  • 41. Outcomes from the medication assisted treatment pilot program for adults with opioid use disorders in rural Colorado.
    Amura CR; Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Cook PF
    Subst Abuse Treat Prev Policy; 2022 Jan; 17(1):1. PubMed ID: 34980179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
    Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
    Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medications for opioid use disorder in pregnancy in a state women's prison facility.
    Knittel AK; Zarnick S; Thorp JM; Amos E; Jones HE
    Drug Alcohol Depend; 2020 Sep; 214():108159. PubMed ID: 32683223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.
    Frost MC; Richards JE; Blosnich JR; Hawkins EJ; Tsui JI; Edelman EJ; Williams EC
    Drug Alcohol Depend; 2022 Aug; 237():109521. PubMed ID: 35716644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM; Noor-E-Alam M; Mohite P; Islam MS; Modestino AS; Peckham AM; Young LD; Young GJ
    J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Automated prediction of risk for problem opioid use in a primary care setting.
    Hylan TR; Von Korff M; Saunders K; Masters E; Palmer RE; Carrell D; Cronkite D; Mardekian J; Gross D
    J Pain; 2015 Apr; 16(4):380-7. PubMed ID: 25640294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
    Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
    Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review.
    Russell C; Law J; Imtiaz S; Rehm J; Le Foll B; Ali F
    Addict Sci Clin Pract; 2023 Aug; 18(1):48. PubMed ID: 37587456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting.
    Morgan JR; Barocas JA; Murphy SM; Epstein RL; Stein MD; Schackman BR; Walley AY; Linas BP
    JAMA Netw Open; 2020 Dec; 3(12):e2029676. PubMed ID: 33320266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medication for opioid use disorder in the Arab World: A systematic review.
    Alawa J; Muhammad M; Kazemitabar M; Bromberg DJ; Garcia D; Khoshnood K; Ghandour L
    Int J Drug Policy; 2022 Apr; 102():103617. PubMed ID: 35182841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Substance use severity as a predictor for receiving medication for opioid use disorder among adolescents: An analysis of the 2019 TEDS.
    Welsh JW; Sitar SI; Hunter BD; Godley MD; Dennis ML
    Drug Alcohol Depend; 2023 May; 246():109850. PubMed ID: 36989708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015-2018.
    Stahler GJ; Mennis J; Stein LAR; Belenko S; Rohsenow DJ; Grunwald HE; Brinkley-Rubinstein L; Martin RA
    Drug Alcohol Depend; 2022 Jul; 236():109498. PubMed ID: 35605535
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using Electronic Medical Records and Clinical Notes to Predict the Outcome of Opioid Treatment Program.
    Cui W; Shah-Mohammadi F; Finkelstein J
    Stud Health Technol Inform; 2023 Jun; 305():568-571. PubMed ID: 37387094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
    Khan A; Khan Q; Kolb E
    J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US.
    Stahler GJ; Mennis J
    Drug Alcohol Depend; 2020 Jul; 212():108067. PubMed ID: 32445926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
    Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
    J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of opioid use disorder using electronic health records: Beyond diagnostic codes.
    Poulsen MN; Nordberg CM; Troiani V; Berrettini W; Asdell PB; Schwartz BS
    Drug Alcohol Depend; 2023 Oct; 251():110950. PubMed ID: 37716289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.